Screener
Corvus Pharmaceuticals CRVS Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Net (loss) income per share, basic | $(0.15) | $0.21 |
| Net loss per share, diluted | $(0.15) | $(0.13) |
| Shares used to compute net (loss) income per share, basic | 89,996,728 | 72,126,496 |
| Shares used to compute net loss per share, diluted | 89,996,728 | 75,152,514 |
| Other comprehensive (loss) income: | ||
| Unrealized loss on marketable securities | (334) | (23) |
| Cumulative foreign currency translation adjustment | 104 | 57 |
| Comprehensive (loss) income | $(13,922) | $15,227 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Corvus Pharmaceuticals's shares (diluted)?
- Corvus Pharmaceuticals (CRVS) reported shares (diluted) of 90M in Q1 2026.
- How has Corvus Pharmaceuticals's shares (diluted) changed year-over-year?
- Corvus Pharmaceuticals's shares (diluted) increased by 19.8% year-over-year, from 75.2M to 90M.
- What is the long-term trend for Corvus Pharmaceuticals's shares (diluted)?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's shares (diluted) has grown at a 18.0% compound annual growth rate (CAGR), from 162.6M to 315.5M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Corvus Pharmaceuticals's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude